Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03140865 · ClinicalTrials.gov registry record

Wake Forest Alzheimer's Disease Clinical Core

A clinical trial of Mild Cognitive Impairment and Alzheimers Disease, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
850
Enrollment target
1
Study location

NCT03140865: Recruiting study of Mild Cognitive Impairment and Alzheimers Disease, sponsored by Wake Forest University Health Sciences.

NCT03140865 is a study of Mild Cognitive Impairment and Alzheimers Disease that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 850 participants, below the 1,266-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03140865, a study of Mild Cognitive Impairment and Alzheimers Disease, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
850 participants
Enrollment target
1
Study location

Study Summary

Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years before the onset of clinical symptoms. This possibility has been incorporated into a model describing stages of AD development, articulated by the NIA/Alzheimer's Association preclinical workgroup of which the Co-Director of the Kulynych Alzheimer's Research Center, Dr. Suzanne Craft, was a member. According to this model, the best hope for countermanding the effects of AD lies in intervening at the earliest possible point in the pathological cascade. There are several important ongoing efforts in adults with preclinical AD that directly target amyloid aggregation. Although this strategy addresses an important aspect of the AD pathological cascade, we believe that addressing metabolic dysfunction affecting glucose and insulin regulation offers a complementary approach, in that it may reduce amyloid burden and toxicity, while also directly enhancing synaptic health, brain metabolism, tau regulation and neurovascular function. The purpose of the ADCC is to identify and characterize early risk factors that predict cognitive decline and dementia in asymptomatic adults and adults with early signs of cognitive impairment. The data obtained from this study, collected at enrollment and follow-up will allow us to examine disease trajectory in individuals with and without prediabetes and other measures of glucoregulatory dysfunction in this process. The enrollees, who will be well-characterized with regard to cognitive and metabolic status through ADCC assessments, will provide an important resource for other local (institution) and national investigations. Data collected from participants enrolled in the ADCC will be stored indefinitely for future investigations.

Primary Outcome

Cognitive measure such as memory, verbal fluency and executive function will be assessed annually, either by phone or in person depending on group.

Study Locations (1)

North Carolina

  • Wake Forest Baptist Health - Winston-Salem

Trial Details

FieldValue
Enrollment Target 850 participants
Start Date 2014-01
Est. Completion 2031-01
Wake Forest University Health Sciences

1,140 total trials

What NCT03140865 shows while recruiting

NCT03140865 is an observational study that tracks outcomes without assigning an intervention. The registered 850 participants enrollment target is mid-sized for trials with a published cap, below the 1,266-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (33% lower).

The record links to 3 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.

NCT03140865 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT03140865 about?

NCT03140865 is a clinical study titled "Wake Forest Alzheimer's Disease Clinical Core". Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years before the onset of clinical symptoms. This possibility has been incorporated into a model describing st...

What is the current status of trial NCT03140865?

This trial is currently recruiting. The enrollment target is 850 participants. The study started on 2014-01. Estimated completion is 2031-01.

What conditions does trial NCT03140865 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment, Alzheimers Disease, Prediabetic State.

Who is sponsoring clinical trial NCT03140865?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03140865 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mild Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03140865's enrollment target sits among peer trials

850 16th of 205 higher than 189 of 205 other Mild Cognitive Impairment trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05846841 · 850 participants · NA

    Personalized Tobacco Treatment in Primary Care (MOTIVATE)

  • NCT05987059 · 850 participants · Phase 2

    Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT

  • NCT06289673 · 850 participants · Phase 4

    Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

  • NCT06526195 · 850 participants · NA

    Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03140865, the US trial registry maintained by the National Library of Medicine. NCT03140865 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.